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ABSTRACT We have subverted a receptor-mediated en-
docytosis event to transport genes into human leukemic cells.
By coupling the natural iron-delivery protein transferrin to the
DNA-binding polycations polylysine or protamine, we have
created protein conjugates that bind nucleic acids and carry
them into the cell during the normal transferrin cycle [Wagner,
E., Zenke, M., Cotten, M., Beug, H. & Birnstiel, M. L. (1990)
Proc. NatI. Acad. Sci. USA 87, 3410-3414]. We demonstrate
here that this procedure is useful for a human leukemic cell
line. We enhanced the rate of gene delivery by (i) increasing the
transferrin receptor density through treatment of the cells with
the cell-permeable iron chelator desferrioxamine, (ii) interfer-
ing with the synthesis of heme with succinyl acetone treatment,
or (iii) stimulating the degradation ofheme with cobalt chloride
treatment. Consistent with gene delivery as an endocytosis
event, we show that the subsequent expression in K-562 cells of
a gene included in the transported DNA depends upon the
cellular presence of the lysosomotropic agent chloroquine. By
contrast, monensin blocks "transfeMnfection," as does incu-
bation of the cells at 18°C.
Rapidly dividing cells and cells programmed to synthesize
large quantities of heme-e.g., neoplastic cells or cells of the
hematopoietic lineage-require elevated levels of iron. Cells
obtain iron complexed with the carrier protein transferrin,
which is then internalized after binding to a specific receptor
(for review, see ref. 1). We have created human transferrin
molecules that retain their ability to bind the transferrin
receptor and are modified by the addition of a nucleic
acid-binding domain (either protamine or polylysine) so that
they can bind and carry nucleic acids into the cell. Complexes
of polylysine-transferrin and DNA, when supplied to cells
expressing the transferrin receptor, result in the uptake and
expression of genes (2, 3) contained in the DNA. We call this
DNA-transfer method "transferrinfection" (2). A similar
strategy, employing the asialoglycoprotein receptor, has
been used by Wu and Wu (4, 5) to deliver DNA to liver cells.
We have shown earlier that transferrin receptors play a
pivotal role in transferrinfection ofDNA and that the DNA is
initially found in endosome-like particles (3). In view of the
endosomal location of the DNA, degradation of at least some
of the introduced nucleic acid would be anticipated as it
reaches the lysosomal compartment. We have reported (2) that
transferrinfection ofDNA works efficiently for chicken eryth-
roid cell lines and primary hematopoietic cells. Working to
adapt the procedure forhuman cell lines, we sought to enhance
the level of transferrinfected DNA in several different ways:
(i) Chloroquine, a compound known to inhibit lysosomal
hydrolytic enzymes such as proteases and nucleases (6), was
included during transferrinfection. The purpose of using this
drug was to try to increase the proportion of unscathed DNA
reaching the nucleus and available for transcription. (ii) Cells
were subjected to conditions that would be expected to
increase transferrin-receptor levels (see legend for Fig. 1).
MATERIALS AND METHODS
Preparation of Transferrinfection Complexes. Human poly-
lysine-transferrin (lysine270) conjugates were prepared and
purified as described (2). The DNA plasmid pRSVL contain-
ing the Photinus pyralis luciferase gene under the control of
the Rous sarcoma virus long terminal repeat enhancer/
promoter (10) was diluted to 0.06 mg/ml in 150 mM NaCl/20
mM Hepes, pH 7.5. This DNA solution was added to a 2- to
3-fold transferrin mass excess of polycation-transferrin at a
maximum concentration of 0.09 mg/ml (as transferrin) in 150
mM NaCl/20 mM Hepes, pH 7.5. Complexes were allowed
to form for 30 min at room temperature before being added
to cells.
Cells and Media. Cells of the human erythroleukemia cell
line K-562 were grown in RPMI 1640 medium (supplemented
with 10% fetal calf serum, penicillin at 100 international
units/ml, streptomycin at 100 ,g/ml, and 2 mM glutamine) at
a density of 200,000-500,000 cells per ml. In some experi-
ments cells were grown for 24-48 hr in the presence of test
compounds, as indicated in the figure legends. In all cases,
just before transferrinfection, the cells were washed twice
with fresh medium and suspended at 150,000 per ml ofRPMI
1640 medium containing, where indicated, 100 ,iM chloro-
quine. In some of the initial experiments, cells were washed
with medium lacking serum, and the transferrinfections were
performed in medium lacking serum. Test experiments
showed that 10% fetal calf serum had no effect on transfer-
rinfection efficiency (results not shown); subsequent exper-
iments included 10% fetal calf serum. The DNA-polylysine-
transferrin complex was added to the cell suspension for 4 hr
at 37°C. At the end of this period, cells were transferred to
fresh medium, either by centrifugation or by removing 90%
of the cell medium, replacing it with fresh prewarmed me-
dium, and repeating this maneuver after the cells resettled to
the bottom of the dish. This procedure lowered chloroquine
levels sufficiently to avoid long-term toxicity. The cells grew
at 37°C for 18-48 hr, as indicated in each figure, after which
they were harvested by centrifugation and washed twice with
phosphate-buffered saline; extracts were then prepared, and
aliquots, standardized for protein content, were analyzed for
luciferase activity (see ref. 2).
RESULTS
Requirement for Chloroquine During the Transferrinfection
Period. We have tested the requirement of the human leu-
kemic cell line K-562 for chloroquine during the 4-hr trans-
ferrinfection period. Luciferase activity was assayed in cells
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FIG. 1. Schematic representation of heme metabolism. Com-
pounds that alter the internal iron levels or modify the level of hemin,
either by decreasing heme synthesis or by increasing heme degra-
dation, modulate transferrin-receptor levels (7). When one treats the
cells with the cell-permeable iron chelator desferrioxamine, the cell
responds to the iron deficit by increasing the number of transferrin
receptors on its surface (7, 8, 25). Succinyl acetone is a potent
inhibitor of the first committed step of heme biosynthesis, 5-
aminolevulinate acid dehydratase (7); treatment ofcells with succinyl
acetone increases cell-surface transferrin receptors (7, 25). When
cobalt chloride is added to cells, heme oxygenase and, hence, heme
degradation is stimulated, and the cell responds by increasing
transferrin-receptor levels (7).
transferrinfected with either 3 or 10 ,tg of DNA (complexed
with a 3-fold mass excess oftransferrin-polylysine conjugate)
for 4 hr either with or without 100 ,M chloroquine. We found
no activity in the absence of chloroquine (Fig. 2). However,
with chloroquine luciferase activity was obtained-greater
quantities of luciferase activity being obtained with higher
quantities of DNA per polylysine-transferrin.
The carboxylic acid ionophore monensin acts on the Golgi
apparatus and is also a potent lysosomotropic agent (11). It
has been reported to interfere with the transferrin cycle by
blocking vesicle fusion and the return of the apotransferrin-
transferrin receptor complex to the cell surface (14). We
tested the transferrinfection with monensin to determine
whether this agent would behave in a manner similar to
chloroquine. Monensin, at low concentration (1-10 ,uM), was
ineffective in stimulating transferrinfection (Fig. 3) and ac-
tually interfered with the delivery of DNA. When cells were
treated with both 100 ,uM chloroquine (which alone gave a
strong luciferase signal) and monensin, the resulting lu-
ciferase activity was negligible (Fig. 3).
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FIG. 2. Influence of chloroquine on transferrinfection. Samples
of K-562 cells (300,000 cells per assay point) were transferrinfected
for 4 hr with either 3 or 10 kkg of pRSVL with or without 100 ,uM
chloroquine (chloro). Extracts were made, and luciferase activity
was measured 48 hr later in aliquots standardized for protein content.
The activity shown is adjusted to represent total activity from the
entire cellular sample.
Effects of Desferrioxamine Pretreatment. K-562 cells were
grown for 20 hr with 50 gM desferrioxamine in an attempt to
elevate the level of transferrin receptor and, in turn, to
increase the amount ofDNA delivered to cells. Both control
cells and desferrioxamine-treated cells expressed increased
luciferase activity with increased DNA supplied to the cells
as a polylysine-transferrin conjugate (1, 3, and 10 ,tg ofDNA,
Fig. 4). We found that a desferrioxamine pretreatment re-
sulted in a 4-fold increase in transferrin receptor number
(M.C., unpublished results) and in a 5-fold increase in lu-
ciferase activity over control cells with 3 gg of DNA and a
15-fold increase with 10 1kg of DNA.
Effects of Desferrioxamine During the Transferrinfection
Period. In the above experiments desferrioxamine was pre-
sent during the transfection period. There was some concern
that this compound might remove iron from the transferrin-
polylysine conjugates-thus blocking binding of the conju-
gates to the transferrin receptors on the cell surface. The
effect of desferrioxamine during the transfection period was
therefore tested directly. Cells, with or without a 48-hr
pretreatment of 50 ;LM desferrioxamine, were transferrin-
fected for 4 hr in the presence of 100 1LM chloroquine with or
without 50 ;LM desferrioxamine. We found that in all cases(with or without desferrioxamine pretreatment) desferriox-
amine during the transferrinfection period enhanced subse-
quent luciferase activity (Fig. 5). Even without desferriox-
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FIG. 3. Influence of monensin on transferrinfection. Transferrinfection was performed as for Fig. 2. During the transferrinfection period
samples included 100 AM chloroquine (chloro); 1, 3, 10, or 30 ,M monensin; or 1 or 10 ,.M monensin plus 100 A±M chloroquine.
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FIG. 4. Influence of desferrioxamine on transferrinfection. K-562
cells were grown with 50 ,uM desferrioxamine (desferr) for 24 hr.
Samples of either control or desferrioxamine-treated cells (300,000
cells per assay point) were transferrmnfected for 4 hr with 1, 3, or 10
j.g of pRSVL in the presence of 100 juM chloroquine. Desferriox-
amine-treated cells also contained 50 gM desferrioxamine during the
transfection period. Cell extracts were made 48 hr after infection, and
luciferase activity was determined as for Fig. 2.
amine pretreatment, the presence of desferrioxamine pro-
duces a 10-fold stimulation of expression. Chloroquine was
required for the desferrioxamine effect. Note that in our
standard procedure the transferrin-polylysine complexes
contain a 50-fold molar excess of iron citrate (over transfer-
rin) to ensure complete iron loading of the transferrin. We
suspect that the cells may well respond to this iron excess by
promptly downregulating the transferrin receptor cycling.
The desferrioxamine present during the transferrinfection
may serve to chelate excess iron and to maintain high
transferrin receptor levels; desferrioxamine may also influ-
ence endosomal "sorting" in subtle ways (see Discussion).
The high expression levels with desferrioxamine pretreat-
ment depended on the presence of chloroquine during the
4-hr transferrinfection period; expression fell to background
levels without chloroquine (Fig. 5). Raising the transferrin
receptor density is apparently not sufficient in itself to elevate
transferrinfection levels. Some additional event, modulated
by chloroquine, limits the DNA expression.
Effects of Cobalt Chloride Pretreatment. Cobalt chloride is
reported (7) to stimulate heme oxygenase activity, which
results in an increase in transferrin-binding activity in HeLa
cells. We tested the hypothesis that cobalt pretreatment also
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FIG. 5. Influence of desferrioxamine (desferr) and chloroquine
(chloro) on transferrinfection. K-562 cells were grown in the pres-
ence of 50 ,uM desferrioxamine for 24 hr. Samples of either control
or desferrioxamine-treated cells (300,000 cells per assay point) were
transfemrnfected for 4 hr with 10 ,ug of pRSVL in the absence or
presence of 100 1.&M chloroquine and 50,uM desferrioxamine, as
indicated. Cell extracts were made 48 hr after infection, and lu-
ciferase activity was determined as for Fig. 2.
increases expression of a transferrinfected luciferase gene
similar to that obtained with desferrioxamine. Cells were
exposed to either 50 ,M desferrioxamine or 130 ,M cobalt
chloride or both compounds for 48 hr before transferrinfec-
tion. In samples pretreated with desferrioxamine, the com-
pound was also present during the transferrinfection period.
Both 130 AtM cobalt chloride and 50 ,M desferrioxamine
yielded similar enhancements of luciferase expression; com-
bination of the two compounds resulted in an additive in-
crease of expression (Fig. 6). The additive effect of desfer-
rioxamine and cobalt was also seen when desferrioxamine
was omitted from the sample during the transfection period.
Although the level of expression was lower without desfer-
rioxamine during transferrinfection, the cobalt plus desfer-
rioxamine-pretreated sample still showed twice the level of
expression relative to the desferrioxamine-pretreated sam-
ple.
Effects of Succinyl Acetone Pretreatment. Succinyl acetone
inhibits 5-aminolevulinic acid dehydratase, the major con-
trolling enzyme for heme biosynthesis. Treatment of cells
with succinyl acetone has been reported (7, 25) to upregulate
transferrin receptor levels. To test the effect of this com-
pound on transferrinfection, K-562 cells were incubated in 50
,uM desferrioxamine, 2 mM succinyl acetone, or a combina-
tion of both compounds for 48 hr. Transferrinfection was
performed for 4 hr in the continued presence of these
compounds with or without 100 ,uM chloroquine. The cells
were harvested 18 hr later and assayed for luciferase activity.
Succinyl acetone pretreatment modestly increased luciferase
activity compared with untreated cells, and this activity
depended on the presence of chloroquine during the trans-
ferrinfection period (Fig. 7). The succinyl acetone stimulation
was not as great as the desferrioxamine or cobalt stimula-
tions; however, the combination of desferrioxamine and
succinyl acetone provided a slight, but reproducible, stimu-
lation over either compound alone.
DISCUSSION
Our initial goal was to develop methods for the transport of
antisense oligonucleotides and ribozymes across the cell
membrane. We soon discovered that the same modified
receptor-mediated-transport system transferred high-molec-
ular-weight plasmids containing the luciferase gene with
relatively high efficiency. This observation allowed us to
rapidly and reliably monitor the introduction of nucleic acids
into the cell and their transfer to the nucleus. Therefore, we
decided to optimize the transferrinfection procedure by using
this simple reporter system for later application of the tech-
nique to antisense oligonucleotides and ribozymes.
In this paper optimal conditions for the introduction of
DNA into K-562 cells are established using a subverted
cellular receptor-mediated endocytosis mechanism, referred
to as transferrinfection (2). The K-562 cells used for our
studies exhibit the response anticipated toward drugs known
to modulate the intracellular level of iron-heme (Fig. 1) and,
consequently, transferrin-receptor levels. Reduction of in-
tracellular iron-heme concentration either by inhibiting for-
mation of porphobilinogen, the heme precursor, with suc-
cinyl acetone or by complexing iron ions with desferrioxam-
ine upregulates transferrin receptors (7-9), and we observed
that under these conditions cells become more receptive to
transferrinfection. Similarly, we have shown that treatment
of cells with cobalt chloride (probably resulting in increased
heme oxygenase degradation ofheme) increases the import of
DNA during transferrinfection of plasmids. In all these cases
combinations of treatment show additive effects, as mea-
sured by luciferase gene expression.
In K-562 cells expression of an imported luciferase gene
depends on the presence of chloroquine during transferrin-
Biochemistry: Cotten et al.
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FIG. 6. Influence of cobalt chloride on transferrinfection. K-562 cells were grown in the presence of 130 ,M cobalt chloride, 50 ,.M
desferrioxamine (desferr), or a combination of both compounds, for 48 hr. Samples of either control or desferrioxamine-treated cells (300,000
cells per assay point) were transferrinfected for 4 hr with 10 Ag of pRSVL in the absence or presence of 100 AM chloroquine (chloro) and/or
50 AM desferrioxamine, as indicated. Cell extracts were made 48 hr after infection, and luciferase activity was determined as for Fig. 2.
fection. We presume that chloroquine inhibits lysosomal
nucleases to a sufficient degree to allow survival, nuclear
import, and expression of at least some of the transfected
pRSVL plasmid molecules. However, a second lysosomo-
tropic agent, monensin, does not facilitate transferrinfection
and actually interferes with it.
We have tested chloroquine at different concentrations and
find that at 50 AM or less chloroquine is nontoxic to cells but
is also ineffective. Chloroquine at the high concentrations
necessary to augment luciferase expression (100 ,uM) is toxic
to the cells upon protracted incubation. Cells exposed to the
drug at 100 ,uM for >12 hr die progressively with incubation
time, although cells appear to tolerate incubation of 4 hr
without deleterious effects. The necessity for chloroquine
inclusion during transfection seen for K-562 cells is by no
means a universal feature of transferrinfection because cell
lines differ considerably with respect to this requirement.
Thus, an erythroblastic chicken cell line shows high levels of
transferrin-mediated DNA importation, even without chlo-
roquine (3). We do not yet understand why cells differ so
drastically in their response to chloroquine during transfer-
rinfection.
As judged from our work with inhibitors, transferrin and
transferrin conjugates appear to follow different pathways in
the vesicular system of the cell. Time-course experiments by
others reveal initial localization of the unmodified transferrin
and receptor in endocytic vesicles near the cell surface of
K-562 cells with subsequent localization in multivesicular
bodies in the peri-Golgi region of the cell (12), followed by
rapid exocytosis (13). The transferrin-receptor system differs
from many other cellular ligands and their receptors in that
the transferrin cycle does not interact with the lysosomal
compartment. As pH is lowered in the endosome, Fe3+ ions
are set free and the apotransferrin and receptor remain
complexed, whereas other ligands and receptors dissociate
under these conditions. The "sorting endosome" (13) elicits
transport of the transferrin receptors by means of the "re-
cycling endosome" to the cell surface-still associated with
transferrin. Other types of ligands are set free with the sorting
endosome at the prevailing low pH, are held back, and enter
"late" endosomes and finally the lysosomal compartment.
Dissociation of the apotransferrin from its receptor occurs at
high pH after the receptors have surfaced from the cell (1).
Monensin, but not chloroquine, apparently stops transferrin
recycling (14) within the peri-Golgi complex, as does chilling
cells to 18TC (13), and prevents the lysosomal routing of
ligands (other than transferring, but, like chloroquine, addi-
tionally exerts effects through alkalinization of the lysosomal
content and/or prelysosomal compartments (11). The behav-
ior of the DNA from the transferrin-polylysine-DNA com-
plex differs from that of the nonconjugated transferrin-
receptor complex in that the DNA probably enters the
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FIG. 7. Influence of succinyl acetone on transferrinfection. K-562 cells were grown in the presence of 2 mM succinyl acetone (SA), 50 #.M
desferrioxamine (desferr), or a combination of both compounds for 48 hr. Samples of either control or desferrioxamine-treated cells (300,000
cells per assay point) were transferrinfected for 4 hr with 10 ,ug of pRSVL in the absence or presence of 100 AM chloroquine (chloro) and/or
50 AuM desferrioxamine, as indicated. Cell extracts were made 48 hr after infection, and luciferase activity was determined as for Fig. 2.
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lysosomal complex, as suggested by the complete inhibition
of transferrinfection by monensin (Fig. 3) or by chilling cells
to 18'C (data not shown) and the strong stimulation of
transferrinfection by chloroquine (Fig. 2). Thus, transferrin-
polylysine-DNA complexes may behave like transferrin-
colloidal gold or transferrin crosslinked with anti-transferrin
antibodies, which are known to become directed to lyso-
somes (15, 16).
Why are we working to develop a new transfection tech-
nique when so many methods are already available? The
simplest answer is that the available techniques are far from
adequate. The major techniques being considered for gene
therapy use-namely, retroviral vectors, electroporation,
CaPO4 precipitation, and microinjection-have numerous
drawbacks. Microinjection is time consuming, and each
individual cell must be manipulated, which is a difficult or
even impossible task for most applications. Retroviral vec-
tors have limited gene capacity and can activate oncogenes
upon insertion in the target chromosome. Electroporation
and CaPO4 precipitation are harsh, unphysiological, and
cause much cell death.
Is transferrinfection any better? Certainly the delivery
capacity, at least in K-562 cells, is as high as any of the
available techniques. We find that transferrinfection of K-562
cells results in 10- to 30-fold higher expression of luciferase
than that obtained with a DEAE-dextran protocol (17).
Transferrinfection can be repeated several times on the same
cell culture to increase the level of DNA transfer without
causing cell death (3). Transferrinfection is applicable to
primary cell cultures (3), but we caution that cells differ
drastically in their response to transferrinfection. Where the
technique works there is no overt limit to DNA size, and thus
far DNA molecules as large as 14,000 base pairs have been
successfully transferred. This is an extra bonus because
eukaryotic genes can be very large. The requirement for
chloroquine for maximal transferrinfection into certain cells
could be a drawback because this requirement might limit
application of the technique in living organisms; however,
this disadvantage may not prevent its use in ex vivo treatment
procedures. Desferrioxamine, on the other hand, is a drug
tolerated at high plasma concentration, which could possibly
be used to increase receptor levels in vivo.
One general advantage of receptor-mediated endocytosis
of DNA is the ability to target DNA to specific cells by
coupling the DNA-binding domain to cell-specific ligands and
thus generating cell-specific DNA-delivery conjugates. As
mentioned above, high levels oftransferrin receptors are seen
in proliferating and/or neoplastic cells (1, 18, 19). We note,
for instance, that normal breast tissue or cervical epithelium,
when challenged with transferrin-receptor antibodies, exhib-
its no significant transferrin-receptor binding, whereas a
majority ofbreast (16 out of22) and almost all uterine cervical
carcinomas (33 out of 34) show extensive reactivity with
anti-transferrin-receptor antibodies (20-23). Transferrin-
receptor expression in leukemia/lymphoma cells seems to
reflect their proliferative status (ref. 24 and references there-
in). It will be worthwhile to test whether transferrinfection
can be extended to cells other than K-562 exhibiting high
levels of transferrin receptor expression.
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